Generated by Rank Math SEO, this is an llms.txt file designed to help LLMs better understand and index this website.

# Abera Bioscience: Abera Bioscience AB is a Swedish biotechnology company developing novel vaccines and immunotherapies based on proprietary outer membrane vesicle (OMV) technology, with a focus on mucosal immunization and infectious diseases.

## Sitemaps
[XML Sitemap](https://aberabio.com/sitemap_index.xml): Includes all crawlable and indexable pages.

## Posts
- [Abera announces the outcome of the exercise of warrants of series TO2025/2026](https://aberabio.com/abera-announces-outcome-exercise-warrants-to2025-2026/): Abera Bioscience AB ("Abera" or the "Company") today announces the outcome of the exercise of warrants of series TO2025/2026, which were issued in connection with the directed share issue announced on 17 July 2025. A total of 958,185 warrants were exercised, corresponding to an exercise rate of 87.7 per cent. Through the exercise of warrants, Abera will receive approximately SEK 7.9 million before transaction costs.
- [Abera submits Clinical Trial Application for vaccine candidate Ab-01.12](https://aberabio.com/aberas-submits-clinical-trial-application-for-ab-01-12/): Abera Bioscience AB today announced that, together with its clinical partner Radboud University Medical Center (Radboud UMC), it has submitted a Clinical Trial Application to the regulatory authorities in the Netherlands to initiate a Phase I clinical trial of its vaccine candidate AB-01.12.
- [Abera’s management and employees acquire shares through exercise of warrants](https://aberabio.com/management-and-employees-acquire-shares-through-exercise-of-warrants/): Board member Mats Wahlström has, in consultation with the Board of Directors, decided to transfer his warrants of series TO2025/2026 to members of Abera Bioscience's management team, employees and fellow board members. The transfer comprises Mats Wahlström's entire holding of 126,739 warrants, corresponding to a total value of SEK 1,039,259.80.
- [Abera completes successful ferret study with intranasal influenza vaccine](https://aberabio.com/abera-completes-successful-ferret-study-with-intranasal-influenza-vaccine/): Abera Bioscience today announced that the Company has completed a ferret study during the spring with its intranasal influenza vaccine candidate. The outcome of the study was very strong and met the Company's highest expectations. Abera is currently preparing a manuscript for publication of the detailed results in a forthcoming scientific journal.
- [Abera publishes scientific article in “Vaccine” demonstrating strong protection with intranasal influenza vaccine candidate](https://aberabio.com/abera-publishes-scientific-article-in-vaccine/): Abera Bioscience AB ("Abera" or the "Company") today announced that a scientific article has been accepted for publication in the peer-reviewed journal Vaccine. The publication, with the title ”Intranasal influenza vaccination using an Outer Membrane Vesicle platform”, presents preclinical data from the development of the Company's intranasal influenza vaccine candidate based on Abera's proprietary OMV platform.
- [CEPI extends support for Abera’s development of the BERA vaccine platform](https://aberabio.com/cepi-extends-support-for-aberas-development-of-the-bera-vaccine-platform/): Abera Bioscience AB ("Abera" or the "Company") today announces that CEPI (Coalition for Epidemic Preparedness Innovations) has decided to extend the ongoing project supporting the development of Abera's BERA vaccine platform and the Company's innovative influenza vaccine candidate. The project period has been extended until December 31, 2026, with the budget remaining unchanged.
- [Kommuniké från årsstämma i Abera Bioscience AB  2026](https://aberabio.com/kommunike-fran-arsstamma-i-abera-bioscience-ab-2026/): Årsstämma 2026 i Abera Bioscience AB (”Abera” eller ”Bolaget”) hölls den 10 juni 2026. Ordförande Anders Ericson höll ett inledande anförande som också återfinnas längre ner i detta pressmeddelande.
- [Abera Bioscience completes GMP production and prepares for clinical start of vaccine candidate Ab-01.12](https://aberabio.com/completes_gmp_production_of_ab-01_12/): Abera Bioscience AB ("Abera" or the "Company") today announces that GMP production of clinical trial material for the Company’s vaccine candidate Ab-01.12 – a first-in-class intranasal vaccine against pneumococci – has been successfully completed. The Company is thereby entering the next phase and is preparing the submission of an application to initiate clinical trials (Clinical Trial Application, CTA) to the relevant regulatory authorities.
- [Delårsrapport Q1 2026 Abera Bioscience AB](https://aberabio.com/delarsrapport-q1-2026-abera-bioscience-ab/): Under kvartalet genomförde vi en riktad nyemission om cirka 10 mSEK till den professionella investeraren Göran Ofsén. Göran lyfte i sitt brev att hans investering baseras på en kombination av potentialen att skapa betydande samhällsnytta – där Aberas teknologi kan bidra till att rädda miljontals liv – och möjligheten till en attraktiv finansiell utveckling. Vi är stolta över förtroendet från en så kunnig och erfaren investerare och vi ser det som ett stort ansvar att fortsätta utveckla Abera med både aktieägarnas värdeskapande och vårt bidrag till global hälsa i fokus.
- [Abera Bioscience publicerar Årsredovisning 2025](https://aberabio.com/abera-bioscience-publicerar-arsredovisning-2025/): Abera Bioscience AB (publ) meddelar idag att bolaget publicerar årsredovisningen för 2025.
- [Notice of Annual General Meeting in Abera Bioscience AB](https://aberabio.com/notice-of-annual-general-meeting-2026/): Aktieägarna i Abera Bioscience AB (publ), org. nr. 556909-0904 (”Bolaget”), kallas härmed till årsstämma onsdagen den 10 juni 2026 kl 13.00 i Uppsala Business Park, Virdings allé 32 i Uppsala.   
- [New publication in npj Vaccines provides important insight into the mechanism of action of Abera’s pneumococcal vaccine Ab-01.12](https://aberabio.com/new-publication-npj-vaccines-mechanism-of-action-omv-vaccines/): Abera Bioscience AB (“Abera” or the “Company”) today announces that a scientific article has been published in the well-renowned journal npj Vaccines. The publication provides new and important insights into the mechanism of action underlying the Company’s vaccine technology and strengthens the scientific foundation of the pneumococcal vaccine candidate Ab-01.12.
- [Presentation from Stora Aktiedagarna published](https://aberabio.com/presentation-from-stora-aktiedagarna-published/): Abera Bioscience publishes a video recording of the presentation given by CEO Maria Alriksson at Aktiespararna’s event “Stora Aktiedagarna” in Stockholm on Tuesday, March 10, 2026.
- [Bokslutskommuniké 2025 Abera Bioscience AB](https://aberabio.com/bokslutskommunike-2025-abera-bioscience-ab/): 2025 har varit ett mycket framgångsrikt år för Abera Bioscience. Under året har bolaget tagit flera avgörande steg som tillsammans positionerar bolaget för nästa viktiga fas i utvecklingen – att ta vår första vaccinkandidat in i kliniska studier. Med unika och starka vetenskapliga resultat, säkrad finansiering och ett tydligt fokus framåt har vi lagt grunden för övergången från ett prekliniskt forskningsbolag till ett kliniskt vaccinbolag.
- [Brev från Aberas nya storägare](https://aberabio.com/brev-fran-aberas-nya-storagare/): Abera Bioscience publicerar idag ett brev från bolagets nya huvudägare Göran Ofsén. Bolaget har fått flera frågor kring den nyemission som nyligen genomfördes där Göran Ofsén investerade 10,0 mSEK i Abera, bakgrunden till investeringen och hans rational för beslutet. Han har därför skrivit ett brev kring detta riktat till Aberas övriga aktieägare som publiceras nedan.
- [Abera Bioscience initiates new studies in pandemic influenza – CEPI approves project extension](https://aberabio.com/abera-initiates-new-studies-in-pandemic-influenza-cepi-approves-extension/): Abera Bioscience today announces that the Company is initiating additional preclinical studies within its influenza program, with a focus on pandemic avian influenza. The studies are conducted in well-established ferret models with high predictability for future responses in humans and are intended to generate a broad and robust data package ahead of the next development step.
- [Abera Bioscience strengthens capital base to accelerate development and expand pipeline](https://aberabio.com/abera-starker-kapitalbasen/): Abera Bioscience AB (“Abera” or the “Company”), which develops innovative mucosal vaccines to prevent life-threatening diseases, today announces that its Board of Directors, based on the authorization granted by the Annual General Meeting held on 11 June 2025, has resolved to carry out a directed share issue of up to 1,869,159 shares. The subscription price is SEK 5.35 per share. The share issue may provide the Company with proceeds of up to approximately SEK 10.0 million.
- [Abera Bioscience strengthens its team to meet a high pace of development](https://aberabio.com/abera-strenghtens-team-to-meet-high-pace/): Abera Bioscience, which develops nasal vaccines based on its proprietary technology platform, is in an intensive development phase in which several vaccine candidates are being advanced in parallel towards clinical development. To ensure continued high execution capacity and long-term competence, the Company is now strengthening its organisation through recruitment.
- [Benefits of mucosal immunization: A New Paradigm in Vaccine Protection](https://aberabio.com/benefits-of-mucosal-immunization/): This page outlines the key benefits of mucosal immunization, the underlying immunological mechanisms, and its potential role in future vaccine development.
- [Delårsrapport Q3 2025 Abera Bioscience AB](https://aberabio.com/delarsrapport-q3-2025-abera-bioscience/): Hösten har varit en intensiv och mycket positiv period för Abera Bioscience. Vi befinner oss i ett avgörande och inspirerande skede där flera års forsknings- och utvecklingsarbete börjar bära frukt och ta oss mot klinik. Det är glädjande att se hur teamet och våra samarbetspartners fortsätter att leverera med fokus, engagemang och hög kvalitet för att förverkliga nästa steg i bolagets utveckling.
- [Artikel: Influensa och kampen mot framtida pandemier](https://aberabio.com/artikel-influensa-och-kampen-mot-framtida-pandemier/): Denna artikel är en fördjupning om influensa och en del i en serie fördjupningsartiklar från Abera Bioscience.
- [Abera Bioscience reports promising long-term data for its nasal influenza vaccine – strong and sustained immune responses demonstrated in new preclinical study](https://aberabio.com/abera-reports-long-term-data-on-nasal-influensa-vaccine/): Abera Bioscience AB (“Abera” or “the Company”) today presents new positive long-term data from a preclinical study of its nasal influenza vaccine candidate.
The results show that the vaccine generates strong and long-lasting immune responses both at the mucosal surfaces and systemically, further strengthening confidence in the company’s mucosal vaccine platform as a future alternative to traditional influenza vaccines.
- [Abera Bioscience awarded £70,000 grant from BactiVac for spray applicator studies ahead of clinical trials of pneumococcal vaccine Ab-01.12](https://aberabio.com/abera-awarded-70000-grant-from-bactivac/): Abera Bioscience AB (“Abera” or the “Company”) has been awarded a £70,000 grant from BactiVac, the Bacterial Vaccines Network. The funding will support studies of the spray applicator intended for use in the upcoming clinical trials of the Company’s pneumococcal vaccine candidate Ab-01.12.
- [Artikel: Pneumokocker och vaccin – en kamp mot en mångfacetterad bakterie](https://aberabio.com/artikel-pneumokocker-och-vaccin-en-kamp-mot-en-mangfacetterad-bakterie/): Denna artikel är en fördjupning inom pneumokocker och en del i en serie fördjupningsartiklar från Abera Bioscience.
- [Delårsrapport Q2 2025 Abera Bioscience AB](https://aberabio.com/delarsrapport-q2-2025-abera-bioscience-ab/): Våren och sommaren har präglats av ett fokuserat arbete som lägger grunden för nästa fas i Aberas utveckling. Jag är stolt över det vi åstadkommit internt och inspirerad av det engagemang jag ser i teamet. I juli meddelade vi en nyemission som säkrar finansieringen för vår första kliniska studie med pneumokockvaccinet. Att emissionen genomförs mitt i sommaren till låg rabatt är ett styrkebesked och intresset för Abera har aldrig varit större. Emissionen leds av USA-baserade Gunnar Sachs och Mats Wahlström som vi inledde ett strategiskt samarbete med för ca två år sedan och som nu intensifieras.
- [Abera announces outcome of directed share issue – the issue was fully subscribed](https://aberabio.com/abera-announces-outcome-of-directed-share-issue-the-issue-was-fully-subscribed/): Abera Bioscience AB (“Abera” or the “Company”) announces the outcome of the directed issue of units that was announced on 17 July 2025. The issue of 1,092,480 units was subscribed to 100 percent. Each unit consists of three (3) shares and one (1) warrant. The subscription price per unit is SEK 19.68, corresponding to SEK 6.56 per share. The Company will thus receive approximately SEK 21.5 million before issue costs. If all warrants in series 2025/2026 are exercised, the Company may receive an additional approximately SEK 9.0 million.
- [Abera awarded an additional SEK 4.7 million grant from CEPI to expand development of nasal influenza vaccine candidate](https://aberabio.com/abera-awarded-an-additional-sek-4-7-million-grant-from-cepi-to-expand-development-of-nasal-influenza-vaccine-candidate/): Abera Bioscience AB ("Abera" or the "Company") has been granted an additional approximately SEK 4.7 million (about USD 450,000) from CEPI (the Coalition for Epidemic Preparedness Innovations). The expanded funding will be used to further optimise the development of production processes that enable faster antigen production, as well as to conduct additional preclinical studies with Abera’s vaccine platform and vaccine candidates. The project, that is now extended, was initiated in October 2024 and will now run until 31 March 2026.
- [Abera Bioscience carries out directed issue of units to finance clinical Phase I study of pneumococcal vaccine candidate Ab-01.12](https://aberabio.com/direct_issue_to_finance_phase_1/): Abera Bioscience AB (“Abera” or the “Company”), which develops innovative mucosal vaccines to prevent life-threatening diseases, today announces that the Board of Directors has resolved, based on the authorization from the Annual General Meeting held on 11 June 2025, to carry out a directed issue of up to 1,092,480 units. Each unit consists of three (3) shares and one (1) warrant. The subscription price per unit is SEK 19.68, corresponding to SEK 6.56 per share. The 2025/2026 series warrants are issued free of charge. The share issue may raise up to approximately SEK 21.5 million before transaction costs and an additional approximately SEK 9.0 million upon full exercise of the warrants.
- [Artikel: Nästa pandemi – varför vaccinet måste vara snabbare än viruset](https://aberabio.com/nasta-pandemi-pandemivaccin/): Denna artikel är en fördjupning inom pandemiberedskap och en del i en serie fördjupningsartiklar från Abera Bioscience.
- [Communiqué from the Annual General Meeting 2025 of Abera Bioscience AB](https://aberabio.com/communique-from-the-annual-general-meeting-2025-of-abera-bioscience-ab/): The 2025 Annual General Meeting (AGM) of Abera Bioscience AB (“Abera” or “the Company”) was held on June 11, 2025. Chairman Anders Ericson delivered an opening address, which is also included further down in this release.
- [Abera demonstrates new strength in its vaccine platform – long-term storage enables faster and more cost-effective pandemic preparedness](https://aberabio.com/demonstrates-new-strength-in-its-vaccine-platform/): Abera Bioscience today announces results from a recently completed study that further demonstrates the potential of its vaccine platform for pandemic preparedness. The study shows that the core component of Abera’s technology – Outer Membrane Vesicles (OMVs) – retains functional even after long-term storage, strengthening the platform’s potential for both stockpiling and cost-efficient vaccine production.
- [Artikel: Mukosala vacciner](https://aberabio.com/artikel-mukosala-vacciner/): Denna artikel är en fördjupning inom mukosala vacciner och en del i en serie fördjupningsartiklar från Abera Bioscience.
- [FAQ: Framtidens vaccin är mukosala – och Abera går i täten](https://aberabio.com/faq-framtidens-vaccin-ar-mukosala/): Abera Bioscience utvecklar nästa generations vacciner mot luftvägsinfektioner – med fokus på nasala vacciner som skyddar där infektionen börjar: i slemhinnorna. Med vår egenutvecklade plattform BERA kan vi snabbt ta fram vacciner som är kostnadseffektiva, nålfria och skyddar mot både sjukdom och smittspridning.
- [Delårsrapport Q1 2025 Abera Bioscience AB](https://aberabio.com/delarsrapport-q1-2025-abera-bioscience-ab/): Året har inletts med flera viktiga framsteg för Abera, vilka stärker vår övertygelse om både bolagets potential och styrkan i vår teknologi.
- [Notice of Annual General Meeting in Abera Bioscience AB](https://aberabio.com/kallelse-arsstamma-2025/): Aktieägarna i Abera Bioscience AB (publ), org. nr. 556909-0904 (”Bolaget”), kallas härmed till årsstämma onsdagen den 11 juni 2025 kl 13.00 i Uppsala Business Park, Virdings allé 32 i Uppsala.  
- [Abera Bioscience publicerar Årsredovisning 2024](https://aberabio.com/abera-bioscience-publicerar-arsredovisning-2024/): Abera Bioscience AB (publ) meddelar idag att bolaget publicerar årsredovisningen för 2024.
- [New study confirms Abera’s vaccine is effective as both spray and powder](https://aberabio.com/new-study-confirms-aberas-vaccine-is-effective-as-both-spray-and-powder/): Abera Bioscience AB (“Abera”) today announces positive results from a preclinical study conducted in collaboration with Orexo AB. The study explored the effect of Abera’s new influenza vaccine candidate in both a liquid nasal spray and a dry powder formulation. Results show that both formulations generated high systemic antibody levels and strong local immune responses in the nasal and lung mucosa.
- [Abera receives positive support from the Swedish Medical Products Agency following regulatory advisory meeting](https://aberabio.com/positive-support-from-mpa-2025/): Abera Bioscience has recently conducted a Scientific Advice meeting with the Swedish Medical Products Agency (MPA) regarding the company’s intranasal vaccine candidate against pneumococcal infections, Ab-01.12. The meeting focused on matters related to quality, safety, efficacy, and the proposed clinical development strategy.
- [Update and In-Depth Information on Abera’s Operations](https://aberabio.com/update-and-in-depth-information-on-aberas-operations/):  Det har hänt mycket i Abera Bioscience verksamhet senaste tiden med många positiva nyheter. Bolaget har fått flertalet frågor och önskemål om fördjupning kring våra nyheter, framsteg och betydelse av dessa varför vi här publicerar en utförligare beskrivning kring relevanta frågeställningar.
- [Förändring i Aberas styrelse](https://aberabio.com/forandring_i_aberas_styrelse/): Abera Bioscience AB (publ) meddelar idag att styrelseledamoten Sohila Zadran på egen begäran avgår från styrelsen av personliga skäl.
- [Bokslutskommuniké 2024 Abera Bioscience AB](https://aberabio.com/bokslutskommunike-2024-abera-bioscience-ab/): 2024 har varit ett år av stark utveckling för Abera Bioscience, där vi tagit flera avgörande steg mot att etablera oss som en ledande aktör inom mukosala vacciner. Under det fjärde kvartalet har vi inte bara bekräftat vår teknologis potential genom lovande prekliniska resultat, utan även säkrat betydande forskningsfinansiering och strategiska samarbeten som stärker vår position inför framtiden.
- [Successful results from Abera’s first study with its new influenza vaccine candidate](https://aberabio.com/first-study-on-new-influenza-vaccine/): Abera Bioscience (“Abera” or “the Company”) is a global leader in mucosal vaccine development, specializes in innovative vaccine candidates based on its proprietary platform technologies. The Company now reports that its first in vivo study with a novel nasal influenza vaccine candidate has delivered promising results in the mouse model. The study confirms that the vaccine induces a strong immune response both systemically and in mucosal tissues, leading to effective protection against disease.
- [Nasal Pneumococcal Vaccines: The Future of Pneumococcal Disease Prevention](https://aberabio.com/nasal-pneumococcal-vaccines/): Mucosal vaccine technologies are transforming how we approach infectious disease prevention. As pneumococcal infections continue to pose a serious health risk, particularly for children and older adults, nasal pneumococcal vaccines represent a game-changing innovation.
- [Abera and Orexo initiate collaboration to develop powder vaccines for prevention of disease and transmission](https://aberabio.com/abera-orexo-initiate-collaboration/): Abera Bioscience and Orexo AB are entering into a collaboration to develop and test Abera’s vaccine candidates in powder formulations. Abera develops mucosal vaccines based on its innovative vaccine platforms and has a pipeline of several preclinical vaccine candidates. Orexo specializes in drug formulations and has a unique formulation technology, AmorphOX, designed to improve the properties of pharmaceutical substances through powder formulations.
- [Abera shows positive results in comparative study with market-leading pneumococcal vaccine](https://aberabio.com/positive-results-in-comparative-study-prevnar/): Abera Bioscience ("Abera" or "the Company") presents very promising results from a comparative study where their pneumococcal vaccine candidate, Ab-01.12, was compared to the world-leading vaccine, Prevnar 13, and studied in combination with it. The study demonstrates that Abera’s vaccine is 1,000 times more effective in preventing colonization (growth) of bacteria in the mucosa of mice compared to Prevnar 13 alone. This aligns with previous results from the company’s preclinical studies. The study also shows that mice vaccinated with a combination of Prevnar 13 and Ab-01.12 exhibit similar protection against colonization as with Ab-01.12 alone.
- [Abera Bioscience receives EU patent approval for key platform patent](https://aberabio.com/abera-bioscience-receives-eu-patent-approval-for-key-platform-patent/): Abera Bioscience AB ("Abera" or "the company") has received the final decision to approve its patent application "Display of heterologous molecules on bacterial cells and membrane vesicles" from the European Patent Office (EPO). The patent covers several effective methods for decorating cells or bacterial vesicles (OMVs) with different particles. It represents an important patent that, together with previously approved patents for the BERA platform technology, strengthens the protection of Abera's leading pneumococcal vaccine candidate and other candidates in the pipeline.
- [Delårsrapport Q3 2024 Abera Bioscience AB](https://aberabio.com/delarsrapport-q3-2024/): Abera Bioscience befinner sig i en mycket spännande position. Mukosala vacciner nämns allt oftare som ett potentiellt genombrott inom både allmän vaccinering och pandemibekämpning, och vi är stolta över att vara en ledande aktör inom detta område. Ett lokalt skydd i slemhinnorna, där vaccinet hindrar smitta från att etablera sig i luftvägarna, innebär inte bara att den vaccinerade skyddas mot sjukdom utan också att smittspridningen minskar markant. Vår plattform, som har testats framgångsrikt på flertalet olika prekliniska vaccinkandidater, har visat sig ge en skyddande effekt som har potential att förändra vaccinbranschen i grunden.
- [Abera takes the next step in developing a new nasal influenza vaccine and initiates in vivo studies with support from CEPI](https://aberabio.com/abera-takes-the-next-step-in-developing-a-new-nasal-influenza-vaccine-and-initiates-in-vivo-studies-with-support-from-cepi/): Abera Bioscience ("Abera" or "the Company"), the world’s leading biotechnology company in mucosal vaccines, announces that it is starting in vivo studies for its new nasal influenza vaccine candidate. The studies are funded by the grant from CEPI - Coalition for Epidemic Preparedness Innovations, which the company previously announced in a pressrelease.
- [Abera awarded grant from CEPI: Immune-boosting bacterial platform could aid nasal vaccines](https://aberabio.com/abera-awarded-grant-from-cepi-immune-boosting-bacterial-platform-could-aid-nasal-vaccines/): Researchers at Abera Bioscience are set to test whether their bacterial-based platform could strengthen intranasal vaccines being developed to protect against epidemic and pandemic threats. Supported by a new CEPI grant of up to US$1 million, Abera Bioscience will investigate the role of bacterial outer membrane vesicles (OMVs) in boosting a special type of protection—known as mucosal immunity—which scientists believe could be key to stopping the onward transmission of viruses. Unlike traditional vaccines, which are commonly injected into muscle, vaccines inhaled into the lungs or sprayed into the nose (the mucosal route) could induce this special type of protection.
- [Abera Bioscience awarded 1 Million SEK grant from Vinnova for further development of nasal pneumococcal vaccine](https://aberabio.com/awarded-1-million-grant-from-vinnova-for-nasal-pneumococcal-vaccine/): Abera Bioscience AB ("Abera" or "the Company") has been awarded a 1 million SEK grant from Vinnova to advance the development of its innovative pneumococcal vaccine, Ab-01.12, towards clinical trials. The vaccine, which is based on the Abera’s OMV platform, is administered as a nasal spray and designed to provide broad protection against all bacterial strains, preventing both disease and transmission.

## Pages
- [Pneumococcal Vaccines](https://aberabio.com/pneumococcal_vaccines/): Pneumococcal infections, caused by Streptococcus pneumoniae, are a leading cause of pneumonia, meningitis, and sepsis, particularly in children, older adults, and immunocompromised individuals. Despite the success of current pneumococcal vaccines, challenges remain, including serotype limitations and high production costs.
- [Contact](https://aberabio.com/contact/): Get in contact with us via the contact form or email.
- [News](https://aberabio.com/news/): press releases Press contact Maria Alriksson, CEO maria.alriksson@aberabio.com +46 (0) 70 433 04 49 News
- [Investors](https://aberabio.com/investors/): Our vaccine development projects
- [Projects](https://aberabio.com/projects/): Abera has an extensive pipeline of mucosal vaccine projects in preclinical stage.
- [Technology](https://aberabio.com/technology/): Abera’s highly efficient vaccine platform technology, BERA, enables display of antigens at the surface of OMVs.
- [About Abera](https://aberabio.com/about/): Abera is dedicated to the development of novel vaccines to save lives and increase health globally.
- [Home](https://aberabio.com/): Abera Bioscience develops next-generation nasal vaccines using a modular OMV platform that enables rapid design, cost-effective production and strong mucosal and systemic immunity.